These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 83747)

  • 1. [Test suitable for assessing the immunocompetence of the tumor host in prostatic carcinoma].
    Klebingat KJ
    Z Urol Nephrol; 1978 Oct; 71(10):753-6. PubMed ID: 83747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative characteristics of the immunologic indicators in patients with prostatic adenoma and cancer].
    Savinov VA; Khalezov SP; Sviridova AM
    Urol Nefrol (Mosk); 1983; (2):17-20. PubMed ID: 6190286
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
    Kastelan M; Kovacić K; Tarle R; Kraljić I; Tarle M
    Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
    Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
    Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer].
    Hübler J; Jávor A
    Orv Hetil; 1993 Jul; 134(28):1529-32. PubMed ID: 7688112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
    Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed-type hypersensitivity in patients with nodular hyperplasia and carcinoma of the prostate.
    Leńko J; Turowski G; Dobrowolski Z
    Acta Med Pol; 1983; 24(1-4):93-101. PubMed ID: 6207706
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL; Deng FM; Feng T
    Zhonghua Yi Xue Za Zhi; 1994 May; 74(5):306-8, 327. PubMed ID: 7525028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Status of the T- and B-lymphocyte systems and autoimmune response in patients with sclerosis of the prostate gland].
    Karpenko VS; Chernyshov VP; Galanina IK; Pereverzev AS; Karpenko EI
    Urol Nefrol (Mosk); 1982; (4):27-30. PubMed ID: 6182670
    [No Abstract]   [Full Text] [Related]  

  • 12. [Changes in immunologic reactivity and nonspecific defense factors in patients with prostatic adenoma after surgery and in relation to the method of anesthesia].
    Riabinskiĭ VS; Gasanov BI; Burov NE; Belopol'skiĭ AA
    Urol Nefrol (Mosk); 1986; (2):43-7. PubMed ID: 2424162
    [No Abstract]   [Full Text] [Related]  

  • 13. Critical evaluation of lymphocyte functions in urological cancer patients.
    Elhilali MM; Paika KD; Brosman S; Fahey JL
    Cancer Res; 1976 Jan; 36(1):132-7. PubMed ID: 1082369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor markers of prostate cancer--evaluation of serum PAP and PA].
    Miki M
    Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostate carcinoma: an immuno-cryothermic answer].
    Gonder MJ; Soanes WS; Ablin RJ
    Z Urol Nephrol; 1970 Jun; 63(6):467-70. PubMed ID: 4097963
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical and immunological studies in patients with prostatic tumors].
    Romics I; Fehér J; Horváth J; Kisbenedek L; Balogh F
    Z Urol Nephrol; 1981 Aug; 74(8):567-70. PubMed ID: 7303981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):77-8. PubMed ID: 8756736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.